Mallinckrodt plc reports second quarter 2023 financial results and reaffirms full year guidance

Reports second quarter net sales of $475.0 million, reflecting a 1.3% growth on a reported and constant currency basis compared to the prior year quarter reports net loss of $747.8 million; adjusted ebitda of $144.0 million; cash on hand of $480.6 million at second quarter end reaffirms 2023 net sales and adjusted ebitda guidance terlivaz® launch exceeds expectations, obtaining approximately 50% of targeted hospital formulary access with continued medical community interest provides update on liquidity and discussions with creditors and opioid disbursement trust dublin , aug. 9, 2023 /prnewswire/ -- mallinckrodt plc (nyse american: mnk) ("mallinckrodt" or the "company"), a global specialty pharmaceutical company, today reported results for the second quarter ended june 30, 2023.1 "mallinckrodt continued to advance our strategic initiatives in the second quarter, delivering results in line with our expectations. i am particularly pleased to share that we achieved year-over-year revenue growth this quarter – an important step forward in our goal to stabilize the business in the near term and return to sustainable growth in the long term," said siggi olafsson, president and chief executive officer.
MNK Ratings Summary
MNK Quant Ranking